DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06720246

Balance

Recruiting

Impact of Bariatric Surgery and Liraglutide on Cognitive-Behavioral Markers of Long-Term Weight Loss in Obesity

Effects of Bariatric Surgery and Pharmacological Therapy with Liraglutide on Motivational and Inhibitory Processes: Cognitive-Behavioral Markers of Long-Term Weight Loss. a Study on Patients with Obesity.

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

50

estimated

Study population

Bariatric Surgery, Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoints

•Reaction times (approach bias)•Accuracy (inhibition)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06720246
Org study IDBALANCE
Secondary IDRC2024Ministero della Salute

Timeline

Milestones

Study start2024-06-26actual
Study first posted2024-12-06actual
Last update posted2024-12-11actual
Primary completion2027-05-01estimated
Study completion2027-05-01estimated

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Bariatric SurgeryObesity / overweight

Eligibility

Who can enroll

Minimum age20 Years
Maximum age60 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Patients will be recruited at the IRCCS Galeazzi-Sant'Ambrogio, Milan.

Inclusion criteria

•Subjects of any ethnicity, aged between 20 and 60 years.
•BMI equal to or greater than 30 kg/m².
•No history of neurological or psychiatric disorders, as confirmed through medical history and neuropsychological screening.
•Signed informed consent and willingness to comply with all study procedures.
•Patients scheduled for surgery, treatment with liraglutide, or a dietary regimen.

Exclusion criteria

•Previous diagnosis of significant neurological conditions (e.g., brain injury or dementia) or major psychiatric disorders.
•Current or past psychopharmacological therapy, if prolonged.
•BMI lower than 30 kg/m².
•Lack of signed informed consent.
•Severe medical conditions, including but not limited to: hypertension, significant cardiac disease, or other disorders that may compromise patient safety.
•Confirmed pregnancy through self-report and/or breastfeeding.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other clinical outcomes

2 endpoints
Primary/protocol endpoint/low confidence

Reaction times (approach bias)

Time frame:Baseline and after treatment (2-4 months)

change from baseline, improvement

Primary/protocol endpoint/low confidence

Accuracy (inhibition)

Time frame:Baseline and after treatment (2-4 months)

change from baseline, improvement

Publications (10)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.